OncoMatch/Clinical Trials/NCT05717699
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
Is NCT05717699 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Ad-TD-nsIL12 for oncolytic virus.
Treatment: Ad-TD-nsIL12 — This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in progressive DIPG patients (NCI-CTCAE V5.0).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Intrinsic Pontine Glioma
Demographics
Prior therapy
Cannot have received: other investigational medications
Other investigational medications within 30 days prior to viral treatment
Cannot have received: any type of vaccine
Administer any type of vaccine within 30 days prior to Ad-TD-nsIL12 administration
Cannot have received: blood transfusions or drugs (such as G-CSF) to treat pancytopenia or other hematological disorders
Blood transfusions or drugs (such as G-CSF) within 28 days before viral treatment to treat pancytopenia or other hematological disorders
Lab requirements
Blood counts
Neutrophils ≥ 1x10^9/L; Platelets > 100x10^9/L; Hemoglobin ≥ 9g/dl; Severe bone marrow failure or hypoplasia not permitted
Kidney function
Severe renal failure not permitted
Liver function
Transaminases (AST and/or ALT) or total bilirubin ≤ 3 times the upper limit of normal
Cardiac function
Severe heart failure not permitted
Serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. Transaminases (AST and/or ALT) or total bilirubin > 3 times the upper limit of normal. Neutrophils < 1x10^9/L. Platelets ≤ 100x10^9/L. Hemoglobin < 9g/dl. Severe bone marrow hypoplasia.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05717699 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior other investigational medications, any type of vaccine, blood transfusions or drugs (such as G-CSF) to treat pancytopenia or other hematological disorders disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages